Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CVR Medical Corp. (CRRVF)
North Vancouver, BC, CA
CVR Medical Corp. operates as a healthcare enterprise, specializing in the research and development of advanced acoustic wave analysis, specifically focusing on subsonic, infrasonic, and low-frequency sound technology for medical applications. The company's key product is a diagnostic instrument called the carotid stenotic scan device, engineered to accurately identify and quantify narrowing within the carotid arteries. This technology is designed to benefit a diverse group, including patients, insurance providers (payors), and medical professionals. Established in 1980, CVR Medical Corp. maintains its corporate headquarters in North Vancouver, Canada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -90.00% | -99.95% | -100.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Devices: +11.2%—
-
EPS growth Medical - Devices: +28.5%-888.9% Q3'22: +0.0% (vs Q3'21)
-
FCF margin FCF growth · Medical - Devices: +30.9%—
-
EBIT margin Medical - Devices: +6.2%—
-
ROIC Medical - Devices: +3.3%— Q3'22: +24.0% (vs Q3'21)
-
Share dilution Medical - Devices: 0.0%+0.1% Q3'22: +5.8% (vs Q3'21)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-1.13× Q3'22: -1.04× (vs Q3'21)
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Erwin Wong | Strategic Financial Consultant | 56.3K | male |
| Darren Day | Chief Executive Officer | — | male |
| Jeremy Poirier | Consultant | — | male |
| Orville Day | Lead Physicist | — | — |
| Paul S. Blunden | President, Director, Medical Advisor & Chief Financial Officer | — | — |
| Philip Bendick | Medical Advisor & Independent Board Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CRRVF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
